Abstract: Described herein are multispecific antibodies targeting IL-13 and IL-18. The multispecific antibodies can be antagonistic and/or therapeutic antibodies targeting IL-13 and IL-18. Also described herein are methods of making said multispecific antibodies, methods of inhibiting IL-13 and IL-18 simultaneously with said multispecific antibodies, and methods of treating an IL-13/IL-18 mediated disorder, such as atopic dermatitis, by administering a multispecific antibody described herein.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.

Abstract: Methods are disclosed for the early non-invasive diagnosing of acute rejection (AR) in a transplanted subject, monitoring AR in a transplanted subject at risk of developing AR, preventing, inhibiting, reducing or treating AR in a transplanted subject, or identifying agents for use in the prevention, inhibition, reduction or treatment of AR, based on genes which are differentially expressed in peripheral blood or transplant biopsy tissues, before full clinical manifestation of AR is detected in the transplanted subject.